ArticleJournal for immunotherapy of cancer2025
CD24 recruits tumor-associated neutrophils to promote the progression of hepatocellular carcinoma.
Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Single-cell spatial landscape of aggrephagy activity stratifies hepatocellular carcinoma neutrophils and delivers a 5-gene diagnostic panel for patient stratification.Translational oncology · 2026Article
- Study on the synergistic efficacy and mechanism of CD24 silencing combined with trastuzumab in HER2-positive breast cancer.Journal of molecular histology · 2026Article
- Single-cell transcriptome analysis identifies neutrophil-related prognostic signatures in hepatocellular carcinoma.Journal of gastrointestinal oncology · 2026Article
- Role of solute carrier family 7 member 7 in cancer: opportunities for tumor microenvironment research.Journal for immunotherapy of cancer · 2026Review
- Targeting TRIM25 as a therapeutic strategy to enhance ferroptosis in glioblastoma cells.Journal of nanobiotechnology · 2026Article
- Histone H4K8 lactylation promotes glioblastoma progression by inducing NUPR1-mediated autophagosome‒lysosome fusion.Theranostics · 2026Article
- CD24 as an innate immune checkpoint in solid tumors: biology, biomarker stratification, and therapeutic translation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe immunosuppressive tumor microenvironment is a significant challenge in the treatment of hepatocellular carcinoma (HCC), necessitating the urgent development of strategies to mitigate its effects.
methodsThe application of bioinformatics methods to predict the expression level of CD24 in HCC and its relationship with the occurrence and development of HCC. Gene-engineered mice and flow cytometry were used to study the immune cell populations regulated by CD24. Cell metabolism analysis, western blotting, and lactate content measurement were employed to assess the impact of CD24 on lactate secretion by HCC cells. Additionally, cell counting kit 8 and colony formation assays were conducted to evaluate the effect of CD24 on the sensitivity of HCC cells to sorafenib. The integration of RNA sequencing, flow cytometry, cell chemotaxis experiments, and ELISA established a robust framework for understanding CD24-mediated neutrophils immune infiltration.
resultsIn this study, we found that CD24 can recruit neutrophils to infiltrate HCC tissues to form tumor-associated neutrophils (TANs) and polarize TANs to a protumor phenotype by promoting lactate secretion by HCC cells, thus promoting the progression of HCC. In addition, targeting CD24 can enhance the sensitivity of HCC cells to sorafenib by reducing the accumulation of TANs.
conclusionsOur results reveal the molecular mechanism by which CD24 promotes HCC progression through recruitment of neutrophils infiltrates, raising new insights into the role of targeting CD24 in driving HCC immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.